Help us: Donate
Follow us on:
×

NAD+ Ameliorates Age-Related Hearing Loss in Mice

This novel approach may help a common sensory problem in the elderly.

Albino mouseAlbino mouse
 

In a preprint published in bioRxiv, scientists have shown that long-term supplementation of nicotinamide riboside (NR), a NAD+ precursor, alleviates the progression of age-related hearing loss in a mouse model [1].

An overlooked hearing impairment

Globally, age-related hearing loss (ARHL) is the most common sensory deficit of older people. Moreover, it is associated with several problems, including cognitive decline, social isolation, and accident risk. However, due to its insidious progression, the disease is often overlooked.

The etiology of ARHL is still poorly understood. Some of its proposed hypotheses involve age-dependent changes in DNA damage accumulation (genomic instability), oxidative stress, mitochondrial dysfunction, and senescence-associated inflammation [2].

NAD+ and hearing

NAD+, a natural co-enzyme, which has been shown to ameliorate some aging hallmarks and several age-related conditions, also plays a role in the auditory system. For example, the researchers previously showed that NAD+ supplementation prevents the progression of hearing loss in a mouse model of premature aging [3]. This led them to conduct this experiment in wild-type mice, in which they expected similar results.

NAD+ in the cochlea

In this paper, the researchers compared the cellular NAD+ levels in the cochleas of young (2-month-old) and aged (12-month-old) mice and found that total NAD+ and relative NAD+/NADH levels were lower in the cochleas of the older animals. This led the researchers to hypothesize that long-term NR supplementation could reverse the age-related reduction of this critical co-enzyme.

NR prevents and alleviates the progression of ARHL in mice

To determine the effects of long-term NR administration on hearing loss in old mice, the researchers administered NR through the drinking water of a treatment group, with a control group receiving unaltered water. Both groups were then tested for hearing capability through an auditory brain response (ABR) system at the ages of 2, 8 and 12 months.

It turned out that the supplementation prevented the progression of ARHL specifically at high sound frequencies (16 and 32 kHz). Another test, the hearing threshold shift, showed that NR even improved high-frequency hearing in a subset of treated mice.

Besides the preventative benefits, the researchers wanted to investigate whether NR can also ameliorate disease progression even after hearing loss has occurred. To address this, mice with confirmed ARHL at the age of 15 months were treated with NR for 1.5 months.

Unfortunately, ABR results showed no changes to the hearing thresholds of this group at any given frequency. However, when individual threshold shifts were investigated, NR administration in the female subgroup resulted in significantly reduced threshold shifts at 24 kHz. These results suggest that NR, even when administered in later life, still benefits already affected mice at certain frequencies.

Lipids as protectors

To investigate the underlying effects of NAD+ on ARHL, the team used RNA sequencing (RNA-seq) to determine the transcriptomic profiles of the cochleas in both the treated and untreated groups. Surprisingly, mitochondria-related RNA profiles were not significantly changed, meaning that the restorative effects might not be explained by a direct NAD+ role in mitochondria homeostasis.

However, they found that NR acted along the PPARγ-CIDEC, -PLIN1, -PCK1 axis, which potentially relates to lipid droplet formation. Combined with evidence that lipid droplets could reduce excessive reactive oxygen species, this led to the hypothesis that NR administration indirectly affects mitochondrial homeostasis and function via this mechanism, thereby protecting cochlear cells from cytotoxic damage.

Conclusion

Age-related hearing loss is one of the most common and cumbersome diseases in the elderly. In a mouse model, long-term supplementation of nicotinamide riboside can increase NAD+ level in the cochlea while preventing and halting ARHL. This suggests a potential novel treatment for age-related hearing loss, and it encourages further studies that translate this mouse evidence into clinical application.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

CONNECT WITH US AND STAY INFORMED
Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension:
Lifespan.io YouTube
Lifespan.io Facebook
Lifespan.io Twitter
Lifespan.io Instagram
Lifespan.io Instagram
Lifespan.io Discord
Thank You!

Literature

[1] Okur, M. N. et al. Long-term NAD+ supplementation prevents the progression of age-related hearing loss in mice. bioRxiv, 2022.2008.2025.505332, doi:10.1101/2022.08.25.505332 (2022).

[2] Wang, J. & Puel, J. L. Presbycusis: An Update on Cochlear Mechanisms and Therapies. J Clin Med 9, doi:10.3390/jcm9010218 (2020).

[3] Okur, M. N. et al. Short-term NAD(+) supplementation prevents hearing loss in mouse models of Cockayne syndrome. NPJ Aging Mech Dis 6, 1, doi:10.1038/s41514-019-0040-z (2020).

CategoryNews
About the author
Yossawat Suwanlikit

Yossawat Suwanlikit

Yossawat is a full-time medical doctor and part-time journalist. He is fascinated with the biogerontology research field and dreams to become an anti-aging doctor in Thailand. He believes that longevity is possible and imminent. In addition to curing patients in the clinic, he continues to conduct basic and translational research in order to improve healthspan as quickly as possible. As a doctor, he will do anything to ascertain that preclinical research can translate into clinical applications. Yossawat loves playing sports, hanging out, and learning from others.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Want the latest longevity news? Subscribe to our Newsletter!